A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Title: A Study to See if BEBT-209 Combined With Chemotherapy Works to Treat People With Triple-Negative Breast Cancer Researchers want to learn if a new drug called BEBT-209 works to treat people with a specific type of breast cancer. This cancer is called locally advanced or metastatic triple-negative breast cancer (TNBC). The study has two parts. In the first part, researchers want to see if the new drug combination can shrink tumors. In the second part, researchers want to see if this treatment helps people live longer. Researchers will put participants into two groups by chance. This is

Trial Details

NCT ID
NCT07544056
Phase
PHASE2 / PHASE3
Sponsor
BeBetter Med Inc
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • BEBT-209 capsules
  • Carboplatin Injection
  • Gemcitabine Hydrochloride for Injection
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Participants must meet all of the following criteria to be eligible for the study:
  • Age and gender: Female, aged 18 to 75 years (inclusive).
  • Informed consent: Voluntarily signed the written informed consent form (ICF).
  • Diagnosis: Pathologically confirmed hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →